The advent of HER2-targeted therapies, such as trastuzumab and pertuzumab, has revolutionized the treatment of HER2+ breast cancer, leading to significant improvements in survival outcomes for patients with metastatic disease [5,6,7]. This evidence concerns the gene ERBB2 and breast carcinoma.